for motion sickness
FDA approved Nereus (tradipitant) for motion sickness on May 4, 2026 — the first new pharmacologic treatment for motion sickness in over 40 years. Distinct program from Vanda's tradipitant gastroparesis NDA which received a CRL earlier.
Motion sickness is a condition where the brain receives conflicting signals about movement, triggering symptoms like nausea, vomiting, and dizziness. Nereus (tradipitant) is an oral medicine that blocks a specific brain receptor (NK1) involved in transmitting nausea signals. By calming this pathway, it could help prevent the debilitating nausea that disrupts travel for those affected.
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Source: ClinicalTrials.gov